Chief Medical Officer

Chief Medical OfficerOur Values· Integrity· Intelligence· InitiativeLos Angeles Area / HybridImmix Biopharma is seeking a motivated physician leader with drug development experience to serve as Chief Medical Officer. This leadership role sits within a growing clinical development organization in the autoimmune and oncology space. You will directly influence the development of our portfolio in autoimmune and oncology indications and help to define the broader clinical development strategy. You will interface with sites, CROs, investigators and advisors. You will collaborate internally with clinical, translational and scientific groups.The ideal candidate will have deep expertise in early to late-stage clinical development and a demonstrable track record of advancing precision medicines from bench to bedside to approval with strong scientific rigor and a thorough understanding of target and disease biology.What You Will DoProvide leadership to a cross-functional, matrix team of physicians, clinical scientists and other development teamsProvide specific therapeutic area expertise to enhance innovation and efficiency in clinical trial design and executionResponsible for the generation and continual refinement of clinical development plansProvide key contribution to IND, NDA, BLA submissions via overseeing medical documentation and active participation in meetings with regulatory agenciesClinical lead for early development study conduct including study design, protocol writing, regulatory documents, CRO interactions, study start up, investigator interactions, data monitoring, health authority interactions, analyses and study reports.Establish and develop relationships with investigators, thought leaders, in close collaboration with the Medical Affairs functionAssist in scientific advisory boards, conference activities, external collaborations and partnershipsProvide medical, disease-specific, and development perspective into specific research programs or broader research initiativesWhat We Look ForMedical Doctor (MD/MBBS/DO) degree with fellowship training in medical hematology/oncology at a US-accredited programFive (5) or more years of FDA-facing clinical development experiencePossess a deep knowledge and understanding of autoimmune diseases and oncology, including drug development paradigms, clinical pharmacology and technical, business, and regulatory approachesOutstanding interpersonal and communication skills both written and oral and ability to communicate complex information clearly and succinctlyEffective skills directed toward driving collaboration, achieving results, influencing, and resolving conflicts across internal and external stakeholdersIn depth understanding of phase I-IV drug developmentYou are passionate about clinical development and precision, and are well connected to external experts and highly credible advisors in the oncology spaceYou have talent and ability in forging and nurturing key partnerships and collaborations with the external scientific community, including academia, governmental organizations, nonprofit organizations and CROsAbout Immix BiopharmaImmix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.